Omeros Corporation Earnings

The next earnings date for Omeros Corporation has not yet been scheduled.

Analyst Estimates of Omeros Corporation Earnings

No Results.
Report DateEstimated Earnings Per Share
No Results.

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Omeros Corporation Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
11/05/2025---$0100.00%
08/14/2025---$-0.53-15.70%
08/06/2025---$0100.00%
05/13/2025Before Market$-0.546.76%
03/31/2025Before Market------
11/07/2024After Market$-0.648.57%
08/07/2024After Market$-0.9714.91%
05/15/2024After Market$-0.63-8.62%
03/26/2024Before Market$-0.1572.73%
11/09/2023After Market$-0.603.23%
08/09/2023Before Market$-0.59-3.51%
05/09/2023After Market$-0.543.57%
03/13/2023After Market$2.05459.65%
11/09/2022After Market$-0.2850.00%
08/09/2022After Market$-0.4924.62%
05/10/2022After Market$-0.5325.35%
03/01/2022After Market$-0.37-2.78%
11/09/2021After Market$-0.3630.77%
08/09/2021After Market$-0.4619.30%
05/10/2021After Market$-0.570.00%
03/01/2021After Market$-0.6013.04%
11/09/2020After Market$-0.66-8.20%
08/10/2020After Market$-0.614.69%
05/11/2020After Market$-0.53-55.88%
03/02/2020After Market$-0.58-16.00%
11/12/2019After Market$-0.3319.51%
08/08/2019After Market$-0.2936.96%
05/09/2019After Market$-0.503.85%
03/01/2019Before Market$-0.2174.07%
11/08/2018After Market$-0.81-5.19%
08/09/2018After Market$-0.70-1.45%
05/10/2018After Market$-0.620.00%
03/01/2018After Market$-0.34-100.00%
11/09/2017After Market$-0.1651.52%
08/08/2017After Market$-0.3313.16%
05/10/2017After Market$-0.345.56%
03/16/2017After Market$-0.4519.64%
11/09/2016After Market$-0.3417.07%
08/09/2016After Market$-0.3236.00%
05/10/2016Before Market$-0.54-25.58%
03/07/2016After Market$-0.4915.52%
11/09/2015After Market$-0.53-12.77%
08/10/2015After Market$-0.4421.43%
05/11/2015After Market$-0.5119.05%
03/16/2015After Market$-0.611.61%
11/10/2014After Market$-0.548.47%
08/11/2014---$-0.535.36%
05/12/2014---$-0.54-20.00%
03/13/2014---$-0.47-23.68%
11/07/2013---$-0.46-4.55%
08/09/2013---$-0.48-26.32%
05/10/2013---$-0.40-2.56%
03/18/2013---$-0.45-32.35%
11/09/2012---$-0.36-5.88%
08/07/2012---$-0.38-5.56%
05/10/2012---$-0.352.78%
03/15/2012---$-0.46-31.43%
11/08/2011---$-0.2923.68%
08/09/2011---$-0.2436.84%
05/10/2011---$-0.3023.08%
03/15/2011---$-0.3234.69%
11/04/2010---$-0.3510.26%
08/10/2010---$-0.36-9.09%
05/12/2010---$-0.31-3.33%
03/31/2010---$-0.28-3.70%
11/19/2009---$-0.3310.81%

More About Omeros Corporation

Country
USA
Full Time Employees
202

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Omeros Corporation Earnings” Can Refer to the Omeros Corporation Earnings Date

Some people say “Omeros Corporation earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Omeros Corporation position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Omeros Corporation Stock on the Earnings Date

If you own Omeros Corporation stock (OMER) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Omeros Corporation might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Omeros Corporation shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Omeros Corporation Earnings

You can contact us any time if you would like to ask questions about Omeros Corporation earnings or anything else related to the stock market.